Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: A search database study

被引:233
作者
Freedland, SJ
Isaacs, WB
Platz, EA
Terris, MK
Aronson, WJ
Amling, CL
Presti, JC
Kane, CJ
机构
[1] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Care Ctr, Baltimore, MD 21205 USA
[4] Vet Adm Med Ctr, Dept Surg, Augusta, GA 30904 USA
[5] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA
[6] Greater Los Angeles Healthcare Syst, Urol Sect, Dept Surg, Vet Adm, Los Angeles, CA USA
[7] Univ Calif Los Angeles, Dept Urol, Sch Med, Los Angeles, CA USA
[8] San Diego Naval Hosp, Dept Urol, San Diego, CA USA
[9] Stanford Univ, Dept Urol, Sch Med,Vet Adm Med Ctr, Urol Sect,Dept Surg, Palo Alto, CA 94304 USA
[10] Univ Calif San Francisco, Urol Sect, Dept Surg, Vet Adm Med Ctr, San Francisco, CA 94143 USA
[11] Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2005.05.525
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Prostate growth and differentiation are under androgenic control, and prior studies suggested that tumors that develop in hypogonadal men are more aggressive. We examined whether prostate weight was associated with tumor grade, advanced disease, or risk of biochemical progression after radical prostatectomy (RP). Patients and Methods We evaluated the association of prostate weight with pathologic tumor grade, positive surgical margins, extracapsular disease, and seminal vesicle invasion using logistic regression and with biochemical progression using Cox proportional hazards regression among 1,602 men treated with BP between 1988 and 2003 at five equal-access medical centers, which composed the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Results In outcome prediction models including multiple predictor variables, it was found that the predictor variable of prostate weight was significantly inversely associated with the outcomes of high-grade disease, positive surgical margins, extracapsular extension (all P <= .004), and biochemical progression (comparing prostate weight < 20 v >= 100 g: relative risk = 8.43; 95% CI, 2.9 to 24.0; P < .001). Similar associations were seen between preoperative transrectal ultrasound-measured prostate volume and high-grade disease, positive surgical margins, extracapsular extension (all P <= .005), seminal vesicle invasion (P = .07), and biochemical progression (P = .06). Conclusion Men with smaller prostates had more high-grade cancers and more advanced disease and were at greater risk of progression after RP. These results suggest that prostate size may be an important prognostic variable that should be evaluated for use pre- and postoperatively to predict biochemical progression.
引用
收藏
页码:7546 / 7554
页数:9
相关论文
共 47 条
[1]  
BERRY SJ, 1986, AM J PHYSIOL, V250, P1039
[2]   Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era [J].
Carter, CA ;
Donahue, T ;
Sun, L ;
Wu, HG ;
McLeod, DG ;
Amling, C ;
Lance, R ;
Foley, J ;
Sexton, W ;
Kusuda, L ;
Chung, A ;
Soderdahl, D ;
Jackman, S ;
Moul, JW .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :4001-4008
[3]   The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis [J].
Chen, SS ;
Chen, KK ;
Lin, ATL ;
Chang, YH ;
Wu, HH ;
Chang, LS .
BJU INTERNATIONAL, 2002, 89 (07) :710-713
[4]   INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGE-D2) PROSTATE-CANCER [J].
CHODAK, GW ;
VOGELZANG, NJ ;
CAPLAN, RJ ;
SOLOWAY, M ;
SMITH, JA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (05) :618-621
[5]  
COFFEY DS, 1990, UROL CLIN N AM, V17, P461
[6]   A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Tomaszewski, JE ;
Wein, A .
UROLOGY, 1998, 52 (04) :631-636
[7]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[8]   Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate cancer and a prostatic specific antigen level of 4 ng./ml. or less [J].
D'Amico, AV ;
Chen, MH ;
Malkowicz, SB ;
Whittington, R ;
Renshaw, AA ;
Tomaszewski, JE ;
Samofalov, Y ;
Wein, A ;
Richie, JP .
JOURNAL OF UROLOGY, 2002, 167 (05) :2025-2030
[9]   Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].
D'Amico, AV ;
Moul, JW ;
Carroll, PR ;
Sun, L ;
Lubeck, D ;
Chen, MH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383
[10]   Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1C disease [J].
Epstein, JI ;
Walsh, PC ;
Carter, HB .
JOURNAL OF UROLOGY, 2001, 166 (05) :1688-1691